Hormone replacement therapies (HRTs) for medical interventions: general types, innovations, and broader market overview

Core HRT categories

The largest HRT segment is sex-steroid replacement, for both women and men. In women, estrogen, often paired with a progestogen, is prescribed primarily for the management of menopausal symptoms such as hot flashes, night sweats, and vaginal atrophy, and for the prevention of postmenopausal bone loss. Multiple formulations exist—oral tablets, transdermal patches and gels, and local vaginal preparations. For men, testosterone therapy is used to treat documented hypogonadism, restoring energy, libido, and muscle mass. Routes include topical gels, intramuscular injections, subcutaneous pellets, intranasal gels, and newer oral testosterone undecanoate products.

Beyond sex steroids, thyroid hormone replacement, most commonly with levothyroxine, is a lifelong therapy for hypothyroidism and remains one of the most frequently prescribed medications worldwide¹Reed, T. (2025, 11 mars). Online GLP-1 sales fuel hormone replacement therapy. Axios. https://www.axios.com/2025/03/11/online-glp-1-sales-fuel-hormone-replacement-therapy. In adrenal insufficiency, hydrocortisone and other glucocorticoids are used to replace cortisol, while congenital adrenal hyperplasia requires both glucocorticoid replacement and androgen suppression. Growth hormone replacement is another critical therapy, used in children and adults with growth hormone deficiency to improve growth, body composition, and metabolic health.

Types of innovations over the past decade

Over the past decade, innovation in HRT has focused on improving safety, convenience, and personalization.

In women’s health

In women’s health, tissue-selective and bioidentical hormone combinations have gained ground. Products combining estradiol with progesterone, as well as other conjugated estrogen products combine effective symptom relief with uterine protection in a single oral dose. Intravaginal dehydroepiandrosterone (DHEA) products address painful intercourse with minimal systemic estrogen exposure.

In men’s health

In men’s androgen therapy, a shift away from injectable-only treatment has produced multiple alternatives. Oral testosterone undecanoate formulations provide an oral route that meets FDA bioequivalence criteria. Intranasal testosterone and approved subcutaneous autoinjectors offer new delivery models that improve adherence and avoid the risk of dermal transfer associated with topical gels. Long-acting injectable testosterone undecanoate and subcutaneous pellets can further extend dosing intervals from weeks to months.

And beyond

Other endocrine fields are experiencing similar transformations. Growth hormone therapy, traditionally delivered by daily injection, now includes once-weekly long-acting formulations²FDA Approves SKYTROFA® (Lonapegsomatropin-tcgd) for the Once-Weekly Treatment of Adults with Growth Hormone Deficiency. (2025, 28 juillet). Ascendis Pharma. https://investors.ascendispharma.com/news-releases/news-release-details/fda-approves-skytrofar-lonapegsomatropin-tcgd-once-weekly. In adrenal insufficiency, modified-release hydrocortisone preparations aim to mimic physiologic cortisol rhythms, potentially improving outcomes and quality of life. Even in thyroid disease, new soft-gel and liquid levothyroxine products have been developed to address absorption variability in select patient groups.

Regulatory and safety landscape

Safety concerns have long shaped HRT practice. Landmark studies such as the Women’s Health Initiative (JAMA) and the Million Women Study in the early 2000s reshaped perceptions of menopausal hormone therapy, highlighting increased risks of breast cancer, stroke, and thromboembolic events in certain populations. As a result, guidelines now emphasize individualized therapy at the lowest effective dose for the shortest appropriate duration.

In men, testosterone safety has been closely scrutinized for cardiovascular risk, erythrocytosis, and prostate effects. Large randomized studies such as TRAVERSE have since clarified risk profiles, leading to FDA class-wide labeling updates in 2025 that removed earlier boxed warnings about cardiovascular events while adding requirements to monitor blood pressure³Lincoff, A. M., Bhasin, S., Flevaris, P., Mitchell, L. M., Basaria, S., Boden, W. E., Cunningham, G. R., Granger, C. B., Khera, M., Thompson, I. M., Wang, Q., Wolski, K., Davey, D., Kalahasti, V., Khan, N., Miller, M. G., Snabes, M. C., Chan, A., Dubcenco, E.,. . . Nissen, S. E. (2023). Cardiovascular Safety of Testosterone-Replacement Therapy. New England Journal Of Medicine, 389(2), 107‑117. https://doi.org/10.1056/nejmoa2215025.

Compounded “bioidentical” hormones, marketed as personalized or natural alternatives, remain a regulatory concern. Unlike FDA-approved products, compounded formulations lack rigorous quality control and standardized evidence, and major medical societies caution against their routine use. At the same time, telemedicine and direct-to-consumer (DTC) models have accelerated access to HRT, providing convenience but raising questions about diagnostic accuracy, monitoring adherence, and payer oversight.

---

Learn more about how our team can support you in your projects related to regulatory framework analyses >

---

Market outlook for the next decade

The next ten years will likely see steady, diversified growth across HRT categories. Analysts forecast global market expansion at ~6–8% per year, driven by demographic aging, increased awareness of endocrine health, and the continued rollout of innovative delivery systems⁴Hormone replacement therapy market Size | Industry Report, 2033. (s. d.). https://www.grandviewresearch.com/industry-analysis/hormone-replacement-therapy-market. North America is expected to maintain market leadership, benefiting from strong reimbursement environments and a robust pipeline of products targeting both men and women⁵Hormone Replacement Therapy market Size, Global Report 2032. (s. d.). https://www.fortunebusinessinsights.com/hormone-replacement-therapy-hrt-market-102543.

Growth drivers will include expanded use of tissue-selective and combination therapies in menopausal care, uptake of oral and patient-friendly testosterone delivery in hypogonadal men, and the adoption of long-acting growth hormone and modified-release adrenal therapies. Integrated care models—telehealth with bundled lab testing and remote monitoring—will further broaden access and retention. However, safety perceptions, payer cost-containment, and regulatory scrutiny of compounded and consumer-directed products will remain important brakes on indiscriminate expansion.

HRT remains an indispensable pillar of modern medicine, addressing both symptomatic and life-threatening hormone deficiencies. The coming decade promises a landscape defined by more personalized, convenient, and physiologically faithful therapies, delivered in increasingly patient-centric care models. Companies that align product design with robust clinical evidence, safety stewardship, and modern distribution channels will be best positioned to capture value in a global market projected to exceed $35–60B by 2030⁶Hormone replacement therapy market Size | Industry Report, 2033. (s. d.). https://www.grandviewresearch.com/industry-analysis/hormone-replacement-therapy-market⁷Hormone Replacement Therapy Market CAGR, size, share, trends, growth, value, key players analysis | Stratistics MRC report. (s. d.). Stratistics MRC. https://www.strategymrc.com/report/hormone-replacement-therapy-market.

Our expert teams at Alcimed have decades of experience working with key players in the HRT space and developing strategies in this field. Don’t hesitate to contact our team!

---

About the author, 

Sid, Manager in Alcimed’s Life Sciences team in the USA